CINECA IRIS Institutional Research Information System

GABBIANI, CHIARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.402
AS - Asia 4.607
EU - Europa 4.138
SA - Sud America 659
Continente sconosciuto - Info sul continente non disponibili 337
AF - Africa 241
OC - Oceania 14
AN - Antartide 1
Totale 22.399
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.088
IT - Italia 1.574
SG - Singapore 1.506
CN - Cina 1.336
SE - Svezia 774
HK - Hong Kong 630
BR - Brasile 531
VN - Vietnam 383
BG - Bulgaria 325
DE - Germania 290
CA - Canada 243
FI - Finlandia 195
KR - Corea 192
RU - Federazione Russa 169
FR - Francia 165
TR - Turchia 164
GB - Regno Unito 158
UA - Ucraina 154
SN - Senegal 114
IN - India 101
CH - Svizzera 87
JP - Giappone 73
CI - Costa d'Avorio 62
BD - Bangladesh 48
AT - Austria 47
IQ - Iraq 35
EE - Estonia 33
AR - Argentina 32
PL - Polonia 29
ES - Italia 25
VE - Venezuela 25
EC - Ecuador 24
MX - Messico 24
NL - Olanda 21
PK - Pakistan 21
BE - Belgio 18
SA - Arabia Saudita 16
ZA - Sudafrica 16
GR - Grecia 15
IE - Irlanda 12
UZ - Uzbekistan 12
JM - Giamaica 11
MA - Marocco 11
ID - Indonesia 10
KE - Kenya 10
MY - Malesia 10
UY - Uruguay 10
AU - Australia 9
CO - Colombia 9
PH - Filippine 9
PY - Paraguay 9
AE - Emirati Arabi Uniti 8
CL - Cile 8
LT - Lituania 8
CZ - Repubblica Ceca 7
JO - Giordania 7
KZ - Kazakistan 7
OM - Oman 7
TT - Trinidad e Tobago 7
AL - Albania 6
BO - Bolivia 6
PA - Panama 6
BJ - Benin 5
BY - Bielorussia 5
EG - Egitto 5
NG - Nigeria 5
TW - Taiwan 5
CR - Costa Rica 4
DO - Repubblica Dominicana 4
IR - Iran 4
NZ - Nuova Zelanda 4
RO - Romania 4
RS - Serbia 4
TN - Tunisia 4
AZ - Azerbaigian 3
GE - Georgia 3
HN - Honduras 3
HU - Ungheria 3
IL - Israele 3
NO - Norvegia 3
PE - Perù 3
TH - Thailandia 3
XK - ???statistics.table.value.countryCode.XK??? 3
BB - Barbados 2
BS - Bahamas 2
DZ - Algeria 2
ET - Etiopia 2
KW - Kuwait 2
LI - Liechtenstein 2
NI - Nicaragua 2
NP - Nepal 2
PS - Palestinian Territory 2
SR - Suriname 2
SV - El Salvador 2
UG - Uganda 2
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
CG - Congo 1
CU - Cuba 1
DK - Danimarca 1
Totale 22.051
Salva come PNG Salva come JPEG
Città #
Woodbridge 1.615
Ashburn 1.207
Fairfield 1.142
Houston 943
Ann Arbor 925
Singapore 771
Santa Clara 626
Hong Kong 624
Milan 520
Seattle 485
Chandler 464
San Jose 451
Cambridge 411
Wilmington 377
Sofia 324
Serra 287
Shanghai 285
Dallas 283
Jacksonville 252
Hefei 237
Beijing 222
New York 205
Seoul 188
Ottawa 183
Boardman 144
Princeton 136
Los Angeles 130
Nanjing 130
Council Bluffs 118
Lawrence 115
Dakar 114
Medford 114
Lauterbourg 108
Izmir 96
Bern 85
Livorno 81
Ho Chi Minh City 78
Helsinki 75
Tokyo 65
Abidjan 62
Jüchen 61
Rome 58
San Diego 56
Buffalo 55
Dearborn 55
Florence 55
São Paulo 48
Des Moines 47
Dong Ket 46
Hanoi 46
Munich 45
Pisa 45
Istanbul 43
Redondo Beach 42
Nanchang 40
Boulder 39
Vienna 39
Tallinn 33
London 30
Fuzhou 26
Frankfurt am Main 25
Ogden 25
Hebei 23
Shenyang 22
Falls Church 21
Changsha 20
Bremen 19
Chicago 19
Redwood City 19
Brooklyn 18
Brussels 18
Kunming 18
Pune 18
Warsaw 18
Chennai 16
Haiphong 16
Baghdad 15
Belo Horizonte 14
Phoenix 14
Jiaxing 13
Montreal 13
Norwalk 13
Tianjin 13
Da Nang 12
Nuremberg 12
Prato 12
Quanzhou 12
Rio de Janeiro 12
Toronto 12
Turku 12
Brasília 11
Dhaka 11
Padova 11
San Giuliano Terme 11
Tashkent 11
Vicopisano 11
Atlanta 10
Baltimore 10
Denver 10
Kent 10
Totale 16.187
Salva come PNG Salva come JPEG
Nome #
Chemistry and Biology of Two Novel Gold(I) Carbene Complexes as Prospective Anticancer Agents 302
New copper(II)/cyclic tetrapeptide system that easily oxidizes to copper(III) under atmospheric oxygen 253
Photocytotoxic Pt(iv) complexes as prospective anticancer agents 253
Selected cytotoxic gold compounds cause significant inhibition of 20S proteasome catalytic activities 250
Exploiting soft and hard X-ray absorption spectroscopy to characterize metallodrug/protein interactions: The binding of [trans-RuCl4(Im)(dimethylsulfoxide)][ImH] (Im = imidazole) to bovine serum albumin 244
X-ray absorption spectroscopy studies of the adducts formed between cytotoxic gold compounds and two major serum proteins 242
Redefining platinum(IV) chemotherapy: α-tocopherol succinate functionalization and nanoparticle encapsulation to improve cisplatin- and oxaliplatin-based therapies 224
Interaction of gold N-heterocyclic carbenes with nucleic acids 223
Potent in vitro antiproliferative properties for a triplatinum cluster toward triple negative breast cancer cells 221
Synthesis, chemical characterization, and biological evaluation of a novel auranofin derivative as an anticancer agent 213
Gold(III) Compounds as anticancer drugs 213
The reaction of artemisinins with hemoglobin: A unified picture 212
Chlorido and bromido oxaliplatin analogues as potential agents for CRC treatment: Solution behavior, protein binding and cytotoxicity evaluation 212
ESI-MS characterisation of protein adducts of anticancer ruthenium(II)-arene PTA (RAPTA) complexes 208
Peculiar Mechanistic and Structural Features of the Carboplatin-Cytochrome c System Revealed by ESI MS analysis 208
Auranofin, Et3PAuCl, and Et3PAuI Are Highly Cytotoxic on Colorectal Cancer Cells: A Chemical and Biological Study 206
Unravelling the Chemical Nature of Copper Cuprizone 205
MECHANISMS OF CYTOTOXICITY OF SELECTED ORGANOGOLD(III) COMPOUNDS 203
The C2 variant of human serum transferrin retains the iron binding properties of the native protein 203
Arene Ruthenium Complexes with Ethacrynic Acid-Modified Ligands: Synthesis, Characterization and Antiproliferative Activity 203
Interaction of a Gold(I) Dicarbene Anticancer Drug with Human Telomeric DNA G-Quadruplex: Solution and Computationally Aided X-ray Diffraction Analysis 203
Structural and Solution Chemistry, Antiproliferative Effects, and DNA and Protein Binding Properties of a Series of Dinuclear Gold(III) Compounds with Bipyridyl Ligands 200
Exploring Metallodrug–Protein Interactions by ESI Mass Spectrometry: The Reaction of Anticancer Platinum Drugs with Horse Heart Cytochrome c 198
Antitumor gold(III) complexes 195
Emerging Protein Targets for Anticancer Metallodrugs: Inhibition of Thioredoxin Reductase and Cathepsin B by Antitumor Ruthenium(II)-Arene Compounds 195
Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs 195
PtI2(DACH), the Iodido Analogue of Oxaliplatin as a Candidate for Colorectal Cancer Treatment: Chemical and Biological Features 195
New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: Mechanistic and pharmacological implications 194
cis-Pt I2(NH3)2: a reappraisal 191
Cisplatin and its dibromido analogue: a comparison of chemical and biological profiles 191
Chemistry, antiproliferative properties, tumor selectivity, and molecular mechanisms of novel gold(III) compounds for cancer treatment: a systematic study 190
ESI mass spectrometry and X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozyme 188
Activity of rat cytosolic thioredoxin reductase is strongly decreased by trans-[bis(2-amino-5- methylthiazole)tetrachlororuthenate(III)]: first report of relevant thioredoxin reductase inhibition for a ruthenium compound 187
Proanthocyanidin glycosides from the leaves of Quercus ilex L. (Fagaceae) 187
An overview of recent advancements in anticancer Pt(IV) prodrugs: New smart drug combinations, activation and delivery strategies 186
Metal-based compounds as prospective antileishmanial agents: Inhibition of Trypanothione reductase by selected gold complexes 186
Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies. 185
Synthesis and Antiproliferative Activity of New Ruthenium Complexes with Ethacrynic Acid-Modified Ligands 185
The copper(II) coordination abilities of three novel cyclic tetrapeptides with -His-Xaa-His- motif 185
Solution chemistry and cytotoxic properties of novel organogold(III) compounds 183
Mass spectrometry and metallomics: A general protocol to assess stability of metallodrug-protein adducts in bottom-up MS experiments 183
Metal compounds as inhibitors of B-amyloid aggregation. Perspectives for an innovative metallotherapeutics on Alzheimer’s disease 182
Antiplasmodial Effects of a few Selected Natural Flavonoids and their Modulation of Artemisinin Activity 182
Nanoparticles of Mg(OH)2: Synthesis and Application to Paper Conservation 179
DOTAP/DOPE and DC-Chol/DOPE Lipoplexes for Gene Delivery studied by Circular Dichroism and Biophysical Techniques 179
Synthesis, Characterization and Photoactivation Studies on the Novel Pt(IV)-Based [Pt(OCOCH3)3(phterpy)] Complex 179
Solution Behaviour and Biomolecular Interactions of Two Cytotoxic trans-Platinum(II) Complexes Bearing Aliphatic Amine Ligands 178
Reactions of medicinally relevant gold compounds with the C-terminal motif of thioredoxin reductase elucidated by MS analysis 178
Anticancer gold N-Heterocyclic carbene complexes: a comparative in vitro and ex vivo study 178
Proteomic and Metallomic Strategies for Understanding the Mode of Action of Anticancer Metallodrugs 177
Hypericins and thioredoxin reductase: Biochemical and docking studies disclose the molecular basis for effective inhibition by naphthodianthrones 177
The copper(II) binding properties of the cyclic peptide c(HGHK) 176
Exploring metallodrug-protein interactions by mass spectrometry: comparisons between platinum coordination complexes and an organometallic ruthenium compound 176
Chemical Modification of Auranofin Yields a New Family of Anticancer Drug Candidates: The Gold(I) Phosphite Analogues 175
Protein metalation by metal-based drugs: reactions of cytotoxic gold compounds with cytochrome c and lysozyme 175
Structure-Function Relationships within Keppler-Type Antitumor Ruthenium(III) Complexes: the Case of 2-Aminothiazolium[trans-tetrachlorobis(2-aminothiazole)ruthenate(III)] 174
Gold(III) complexes with 2-substituted pyridines as experimental anticancer agents: Solution behavior, reactions with model proteins, antiproliferative properties 174
The molecular mechanisms of antimetastatic ruthenium compounds explored through DIGE proteomics 174
Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study 173
The influence of auranofin, a clinically established antiarthritic gold drug, on bone metabolism: analysis of its effects on human multipotent adipose-derived stem cells, taken as a model 172
2D-DIGE analysis of ovarian cancer cell responses to cytotoxic gold compounds 169
Outstanding plasmodicidal properties within a small panel of metallic compounds: Hints for the development of new metal-based antimalarials 168
Antiproliferative effects of two gold(I)-N-heterocyclic carbene complexes in A2780 human ovarian cancer cells: A comparative proteomic study 167
Ruthenium arene complexes with triphenylphosphane ligands: Cytotoxicity towards pancreatic cancer cells, interaction with model proteins, and effect of ethacrynic acid substitution 166
Proteomic analysis of ovarian cancer cell responses to cytotoxic gold compounds 162
Cytotoxic Ag(I) and Au(I) NHC-carbenes bind DNA and show TrxR inhibition 162
Medicinal gold compounds form tight adducts with the copper chaperone Atox-1: biological and pharmacological implications. 161
Novel platinum(II) compounds with O,S bidentate ligands: Synthesis, characterization, antiproliferative properties and biomolecular interactions 161
Butyltin(IV) benzoates: inhibition of thioredoxin reductase, tumor cell growth inhibition, and interactions with proteins 159
Selected gold compounds cause pronounced inhibition of Falcipain 2 and effectively block P. falciparum growth in vitro 159
A focus on the biological targets for coinage metal-NHCs as potential anticancer complexes 159
Reactivity of an antimetastatic organometallic ruthenium compound with metallothionein-2: relevance to the mechanism of action 158
Trans-cis-cis-[RuCl(2)(DMSO)(2)(2-amino-5-methyl-thiazole)(2)], (PMRu52), a novel ruthenium(II) compound acting as a strong inhibitor of cathepsin B 157
Synthesis, Structural Characterization, Solution Behavior, and in Vitro Antiproliferative Properties of a Series of Gold Complexes with 2-(2'-Pyridyl)benzimidazole as Ligand: Comparisons of Gold(III) versus Gold(I) and Mononuclear versus Binuclear Derivatives 157
Protein metalation by two structurally related gold(I) carbene complexes: An ESI MS study 157
The X-ray Structure of the Adduct between NAMI-A and Carbonic Anhydrase Provides Insights into the Reactivity of this Metallodrug with Proteins 156
Thioredoxin reductase, an emerging target for anticancer metallodrugs. Enzyme inhibition by cytotoxic gold(III) compounds studied with combined mass spectrometry and biochemical assays 156
New platinum-oxicam complexes as anti-cancer drugs. Synthesis, characterization, release studies from smart hydrogels, evaluation of reactivity with selected proteins and cytotoxic activity in vitro 156
Reactivity and Biological Properties of a Series of Cytotoxic PtI(2)(amine)(2) Complexes, Either cis or trans Configured 156
124I Radiolabeling of a AuIII-NHC Complex for In Vivo Biodistribution Studies 156
Metal-based drugs for malaria, trypanosomiasis and leishmaniasis: recent achievements and perspectives 155
Reactions of metallodrugs with proteins: selective binding of phosphane-based platinum(II) dichlorides to horse heart cytochrome c probed by ESI MS coupled to enzymatic cleavage. 155
Chemistry and biology of three representative gold(III) compounds as prospective anticancer agents 155
Triethylphosphine gold iodide (I), the iodido analogue of Auranofin: comparative studies of a potential antineoplastic agent 155
Peculiar features in the crystal structure of the adduct formed between cis-PtI2(NH3)2 and hen egg white lysozyme. 155
Biophysical Characterization of Adducts Formed between Anticancer Metallodrugs and Selected Proteins: New Insights from X-ray Diffraction and Mass Spectrometry Studies 154
The mode of action of anticancer gold-based drugs: A structural perspective 153
New insights into the molecular mechanisms of selected anticancer metal compounds through bioinformatic analysis of proteomic data 152
Synthesis, characterization and DNA interactions of [Pt3(TPymT)Cl3], the trinuclear platinum(II) complex of the TPymT ligand 152
Cell and Cell-Free Mechanistic Studies on Two Gold(III) Complexes with Proven Antitumor Properties 151
Interactions of the organogold(III) compound Aubipyc with the copper chaperone Atox1: A joint mass spectrometry and circular dichroism investigation 150
Nitrate as a probe of cytochrome c surface: Crystallographic identification of crucial "hot spots" for protein-protein recognition 150
Insights on the mechanism of thioredoxin reductase inhibition by Gold N-heterocyclic carbene compounds using the synthetic linear Selenocysteine containing C-terminal peptide hTrxR(488-499): An ESI-MS investigation 150
Thermodynamic Evaluation of the Interactions between Anticancer Pt(II) Complexes and Model Proteins 150
Aluminum, copper, iron and zinc differentially alter amyloid-Abeta(1-42) aggregation and toxicity 147
Ruthenium anticancer drugs and proteins: a study of the interactions of the ruthenium(III) complex imidazolium trans-[tetrachloro(dimethyl sulfoxide)(imidazole)ruthenate(III)] with hen egg white lysozyme and horse heart cytochrome c 147
First Crystal Structure for a Gold Carbene-Protein Adduct 147
Mechanistic Insights Into the Anticancer Properties of the Auranofin Analog Au(PEt3)I: A Theoretical and Experimental Study 147
Organogold(III) compounds as experimental anticancer agents: chemical and biological profiles 146
Structural and solution chemistry, protein binding and antiproliferative profiles of gold(I)/(III) complexes bearing the saccharinato ligand 146
Totale 18.077
Salva come PNG Salva come JPEG
Categoria #
all - tutte 61.371
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 61.371
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.537 0 90 169 129 267 168 62 90 62 13 141 346
2022/20231.858 274 218 133 139 147 239 47 155 375 25 79 27
2023/20241.722 247 208 294 127 283 282 56 32 27 20 46 100
2024/20254.034 5 136 25 252 400 392 405 170 377 526 497 849
2025/20264.126 246 579 427 313 322 411 614 280 283 379 147 125
2026/2027346 122 224 0 0 0 0 0 0 0 0 0 0
Totale 22.399